Lupus nephritis

Lupus nephritis is kidney inflammation caused by systemic lupus erythematosus, occurring when immune complexes deposit within the kidney's filtering structures and trigger an inflammatory response. It's one of the most significant organ complications of lupus, affecting a substantial proportion of people with the condition at some point.

This isn't fully understood, but factors including specific genetic predispositions, the pattern and level of certain lupus-related antibodies, and possibly environmental triggers are thought to influence which patients develop kidney involvement. Ongoing research continues to refine understanding of these risk factors.

Symptoms can range from none at all, detected only through routine screening urine and blood tests, to significant swelling, high blood pressure, and visibly abnormal urine as the condition progresses. Because early-stage lupus nephritis can be silent, regular monitoring is recommended for everyone with a lupus diagnosis.

Yes, it's considered one of the most significant organ-threatening complications of lupus, with the potential to progress to kidney failure if not adequately treated, though outcomes have improved substantially with modern immunosuppressive treatment. Early detection through regular monitoring is a key factor in achieving good long-term outcomes.

Lupus has a recognised genetic predisposition, and various specific genes are being studied for their role in kidney involvement, but no single gene determines who will develop lupus nephritis. A family history of lupus or related autoimmune conditions increases overall risk of developing lupus, including its kidney complications.

Yes, with appropriate immunosuppressive treatment, a substantial proportion of people with lupus nephritis achieve full or partial remission, meaning significant reduction in kidney inflammation and protein loss in the urine. Sustained remission generally correlates with better long-term kidney outcomes.

Treatment is tailored to the specific biopsy classification and severity, typically involving an intensive induction phase with immunosuppressive medication to control active inflammation, followed by longer-term maintenance treatment to sustain remission and prevent relapse. Regular monitoring of kidney function and urine tests tracks response throughout.

Ongoing monitoring typically involves regular blood pressure checks, urine testing for protein and blood, and blood tests assessing kidney function and lupus disease activity, continuing indefinitely given the risk of relapse even after achieving remission. Your nephrology and rheumatology teams will coordinate this long-term follow-up.

Proliferative lupus nephritis (Classes III and IV) involves more active, widespread inflammation and cell proliferation within the kidney, generally needing more intensive treatment, while non-proliferative forms (such as Class V, membranous lupus nephritis) involve a different pattern of damage with somewhat different treatment considerations. Kidney biopsy classification guides this important distinction.

Anyone with lupus should have regular kidney monitoring, and any new abnormal findings should prompt nephrology assessment promptly. Private nephrology consultations can typically be arranged within about two weeks, considerably faster than standard NHS waiting times.